Strategies for enhanced radiation delivery in patients with lung cancer.
Since the 1970s primary management for regionally advanced non-small cell lung cancer has shifted from radiotherapy alone to sequential chemoradiation to concurrent chemoradiation. The increase in survival with these approaches has been small; an approximately 3-4 month per decade increase in median survival. Future avenues to improve on these outcomes could involve: i)dose-intense radiotherapy; ii) better target delineation; and iii) combining molecularly targeted agents with optimised radiation therapy. However, to accomplish this, techniques to control tumour motion and decrease toxicity must be developed.
Mañon
Rafael
R
University of Wisconsin, Department of Radiotherapy, K4/B100, 600 Highland Avenue, Madison, WI 53792, USA.
Mehta
Minesh
M
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate; D013997:Time Factors
D000970:Antineoplastic Agents